387 related articles for article (PubMed ID: 21125681)
1. Metabolic alterations and targeted therapies in prostate cancer.
Flavin R; Zadra G; Loda M
J Pathol; 2011 Jan; 223(2):283-94. PubMed ID: 21125681
[TBL] [Abstract][Full Text] [Related]
2. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
O'Brien AJ; Villani LA; Broadfield LA; Houde VP; Galic S; Blandino G; Kemp BE; Tsakiridis T; Muti P; Steinberg GR
Biochem J; 2015 Jul; 469(2):177-87. PubMed ID: 25940306
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
4. Activation of AMP-activated Protein Kinase by Metformin Induces Protein Acetylation in Prostate and Ovarian Cancer Cells.
Galdieri L; Gatla H; Vancurova I; Vancura A
J Biol Chem; 2016 Nov; 291(48):25154-25166. PubMed ID: 27733682
[TBL] [Abstract][Full Text] [Related]
5. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives.
Menendez JA
Biochim Biophys Acta; 2010 Mar; 1801(3):381-91. PubMed ID: 19782152
[TBL] [Abstract][Full Text] [Related]
6. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
Zadra G; Priolo C; Patnaik A; Loda M
Clin Cancer Res; 2010 Jul; 16(13):3322-8. PubMed ID: 20423984
[TBL] [Abstract][Full Text] [Related]
7. The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.
Vazquez-Martin A; Corominas-Faja B; Cufi S; Vellon L; Oliveras-Ferraros C; Menendez OJ; Joven J; Lupu R; Menendez JA
Cell Cycle; 2013 Jan; 12(2):207-18. PubMed ID: 23287468
[TBL] [Abstract][Full Text] [Related]
8. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis.
Ma J; Duan W; Han S; Lei J; Xu Q; Chen X; Jiang Z; Nan L; Li J; Chen K; Han L; Wang Z; Li X; Wu E; Huo X
Oncotarget; 2015 Aug; 6(25):20993-1003. PubMed ID: 25895130
[TBL] [Abstract][Full Text] [Related]
9. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
Popovics P; Frigo DE; Schally AV; Rick FG
Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.
Di Vizio D; Adam RM; Kim J; Kim R; Sotgia F; Williams T; Demichelis F; Solomon KR; Loda M; Rubin MA; Lisanti MP; Freeman MR
Cell Cycle; 2008 Jul; 7(14):2257-67. PubMed ID: 18635971
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.
Menendez JA; Lupu R
Nat Rev Cancer; 2007 Oct; 7(10):763-77. PubMed ID: 17882277
[TBL] [Abstract][Full Text] [Related]
12. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.
Khan AS; Frigo DE
Nat Rev Urol; 2017 Mar; 14(3):164-180. PubMed ID: 28169991
[TBL] [Abstract][Full Text] [Related]
13. Anticancer properties of pomolic acid-induced AMP-activated protein kinase activation in MCF7 human breast cancer cells.
Youn SH; Lee JS; Lee MS; Cha EY; Thuong PT; Kim JR; Chang ES
Biol Pharm Bull; 2012; 35(1):105-10. PubMed ID: 22223345
[TBL] [Abstract][Full Text] [Related]
14. Increased lipogenesis in cancer cells: new players, novel targets.
Swinnen JV; Brusselmans K; Verhoeven G
Curr Opin Clin Nutr Metab Care; 2006 Jul; 9(4):358-65. PubMed ID: 16778563
[TBL] [Abstract][Full Text] [Related]
15. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.
Zadra G; Photopoulos C; Tyekucheva S; Heidari P; Weng QP; Fedele G; Liu H; Scaglia N; Priolo C; Sicinska E; Mahmood U; Signoretti S; Birnberg N; Loda M
EMBO Mol Med; 2014 Apr; 6(4):519-38. PubMed ID: 24497570
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.
Fritz V; Benfodda Z; Rodier G; Henriquet C; Iborra F; Avancès C; Allory Y; de la Taille A; Culine S; Blancou H; Cristol JP; Michel F; Sardet C; Fajas L
Mol Cancer Ther; 2010 Jun; 9(6):1740-54. PubMed ID: 20530718
[TBL] [Abstract][Full Text] [Related]
17. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
18. Androgens and the control of lipid metabolism in human prostate cancer cells.
Swinnen JV; Verhoeven G
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):191-8. PubMed ID: 9699873
[TBL] [Abstract][Full Text] [Related]
19. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome.
Kusunoki J; Kanatani A; Moller DE
Endocrine; 2006 Feb; 29(1):91-100. PubMed ID: 16622296
[TBL] [Abstract][Full Text] [Related]
20. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
